| Title | Cancer Gene Therapy |
| Abbreviation | Cancer Gene Ther. |
| Publication Type | Journal |
| Subject Area, Categories, Scope | Cancer Research (Q1); Molecular Biology (Q1); Molecular Medicine (Q1) |
| h-index | 101 |
| Overall Rank/Ranking | 1851 |
| SCImago Journal Rank (SJR) | 1.727 |
| Impact Score | 5.01 |
| Publisher | Springer Nature |
| Country | United States |
| ISSN | 14765500, 09291903 |
| Best Quartile | Q1 |
| Coverage History | 1994-2025 |
Cancer Gene Therapy publishes the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene transfer/gene therapy as applied to cancer research. Types of articles published include original research articles, case reports, preliminary communications, review articles in the main fields of drug resistance/sensitivity, gene therapy, tumor suppressor and anti-oncogene therapy, cytokine/tumor immunotherapy, etc., industry perspective, and letters to the editor.
Cancer Gene Therapy is a journal covering the technologies/fields/categories related to Cancer Research (Q1); Molecular Biology (Q1); Molecular Medicine (Q1). It is published by Springer Nature. The overall rank of Cancer Gene Therapy is 1851. According to SCImago Journal Rank (SJR), this journal is ranked 1.727. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 101. The best quartile for this journal is Q1.
The ISSN of Cancer Gene Therapy journal is 14765500, 09291903. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Cancer Gene Therapy is cited by a total of 2291 articles during the last 3 years (Preceding 2024).
The Impact IF 2024 of Cancer Gene Therapy is 5.01, which is computed in 2025 as per its definition. Cancer Gene Therapy IF is increased by a factor of 0.05 and approximate percentage change is 1.01% when compared to preceding year 2023, which shows a rising trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
Impact IF 2024 of Cancer Gene Therapy is 5.01. If the same upward trend persists, Impact IF may rise in 2025 as well.
| Year | Impact IF |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 5.01 |
| 2023 | 4.96 |
| 2022 | 6.29 |
| 2021 | 5.33 |
| 2020 | 4.74 |
| 2019 | 3.94 |
| 2018 | 4.70 |
| 2017 | 3.91 |
| 2016 | 3.60 |
| 2015 | 2.76 |
| 2014 | 2.83 |
Cancer Gene Therapy has an h-index of 101. It means 101 articles of this journal have more than 101 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.
The ISSN of Cancer Gene Therapy is 14765500, 09291903. ISSN stands for International Standard Serial Number.
An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.
The overall rank of Cancer Gene Therapy is 1851. According to SCImago Journal Rank (SJR), this journal is ranked 1.727. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
| Year | SJR |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 1.727 |
| 2023 | 1.457 |
| 2022 | 1.384 |
| 2021 | 1.207 |
| 2020 | 1.535 |
| 2019 | 0.930 |
| 2018 | 1.233 |
| 2017 | 1.359 |
| 2016 | 1.098 |
| 2015 | 1.014 |
| 2014 | 0.930 |
| Year | Ranking |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 1851 |
| 2023 | 2372 |
| 2022 | 2440 |
| 2021 | 3029 |
| 2020 | 2185 |
| 2019 | 4807 |
| 2018 | 3183 |
| 2017 | 2718 |
| 2016 | 3822 |
| 2015 | 4363 |
| 2014 | 4782 |
Cancer Gene Therapy is published by Springer Nature. It's publishing house is located in United States. Coverage history of this journal is as following: 1994-2025. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.
Visit the official website of the journal/conference to check the further details about the call for papers.
The IS0 4 standard abbreviation of Cancer Gene Therapy is Cancer Gene Ther.. This abbreviation ('Cancer Gene Ther.') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.
ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.
If your research field is/are related to Cancer Research (Q1); Molecular Biology (Q1); Molecular Medicine (Q1), then please visit the official website of this journal.
The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.
It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.
The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.
Cancer Gene Therapy latest impact IF is 5.01. It's evaluated in the year 2024. The highest and the lowest impact IF or impact score of this journal are 6.29 (2022) and 2.76 (2015), respectively, in the last 11 years. Moreover, its average IS is 4.37 in the previous 11 years.
The Cancer Gene Therapy has an SJR (SCImago Journal Rank) of 1.727, according to the latest data. It is computed in the year 2025. In the past 11 years, this journal has recorded a range of SJR, with the highest being 1.727 in 2024 and the lowest being 0.930 in 2019. Furthermore, the average SJR of the Cancer Gene Therapy over the previous 11-year period stands at 4.37.
The latest h-index of the Cancer Gene Therapy is 101.
The Cancer Gene Therapy is published by the Springer Nature, with its country of publication being the United States.
The Cancer Gene Therapy is currently ranked 1851 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 11 years, this journal has experienced varying rankings, reaching its highest position of 1851 in 2024 and its lowest position of 4807 in 2019.
The standard ISO4 abbreviation for the Cancer Gene Therapy is Cancer Gene Ther..
Cancer Gene Therapy is classified as a journal that the Springer Nature publishes.
The Cancer Gene Therapy encompasses the following areas:
For a more comprehensive understanding of its scope, check the official website of this journal.
The Cancer Gene Therapy is assigned the following International Standard Serial Numbers (ISSN): 14765500, 09291903.
The best quartile for the Cancer Gene Therapy is Q1 (2024).
The Cancer Gene Therapy coverage history can be summarized as follows: 1994-2025.
| Journal/Conference/Workshop/Book Title | Type | Ranking | Publisher | h-index | Impact Score |
|---|---|---|---|---|---|
| Journal of Business Economics and Management | journal | 9811 | Vilnius Gediminas Technical University | 55 | 2.84 |
| Journal of Field Archaeology | journal | 7683 | Maney Publishing | 48 | 1.85 |
| Applied Ecology and Environmental Research | journal | 19122 | Corvinus University of Budapest | 48 | 0.84 |
| CESifo Economic Studies | journal | 17776 | Oxford University Press | 36 | 0.89 |
| Milan Journal of Mathematics | journal | 5131 | Birkhauser Verlag Basel | 31 | 0.74 |
| Journal of Immigrant and Refugee Studies | journal | 7357 | Routledge | 39 | 2.17 |
| Journal of Imaging Science and Technology | journal | 22021 | Society for Imaging Science and Technology | 45 | 0.61 |
| Rudarsko Geolosko Naftni Zbornik | journal | 14286 | Faculty of Mining, Geology and Petroleum Engineering University of Zagreb | 22 | 1.78 |
| HOMO- Journal of Comparative Human Biology | journal | 17447 | Elsevier B.V. | 40 | 1.17 |
| International Journal of Ozone Therapy | journal | 26290 | Centauro SRL | 6 | 0.00 |
| Year | Impact Score (IS) |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 5.01 |
| 2023 | 4.96 |
| 2022 | 6.29 |
| 2021 | 5.33 |
| 2020 | 4.74 |
| 2019 | 3.94 |
| 2018 | 4.70 |
| 2017 | 3.91 |
| 2016 | 3.60 |
| 2015 | 2.76 |
| 2014 | 2.83 |
